DDX47: A Potential Drug Target and Biomarker for Dystonia (G51202)

Target Name: DDX47

NCBI ID: G51202

DDX47

DDX47: A Potential Drug Target and Biomarker for Dystonia

The protein encoded by the gene DDX47 (Dystrophin-like protein 47) is a key regulator of muscle strength and function. It is a member of the dystrophin gene family, which is responsible for the development and maintenance of muscle mass and strength in humans. Mutations in the dystrophin gene have been linked to a variety of muscle-related diseases, including dystonia, muscle weakness and myopathies.

While the exact function of DDX47 is not yet fully understood, it is known to play a role in the regulation of muscle cell survival and growth. It has been shown to promote muscle cell proliferation and survival, as well as modulate the activity of genes involved in muscle development and function.

Disease association

The search for potential drug targets and biomarkers for dystrophies has led to the identification of DDX47 as a potential target. Studies have shown that individuals with dystonia, a progressive muscle-wasting disease, have lower levels of DDX47 than those without the disease. This suggests that modulating DDX47 activity may be a promising strategy for the development of new treatments for dystonia.

Preclinical studies

In addition to its potential as a drug target, DDX47 has also been shown to be a potential biomarker for dystonia. The dystonia mouse model has been widely used to study the effects of drugs on muscle strength and function. Using this model, researchers have shown thatDDX47 levels are reduced in dystonic muscles and that supplementation with the dystrophin gene restore muscle mass and strength in these muscles.

While further studies are needed to fully understand the potential of DDX47 as a drug target and biomarker for dystonia, its potential as a therapeutic agent is an exciting area of 鈥嬧?媟esearch.

Clinical applications

The study of DDX47 as a potential drug target and biomarker for dystonia is an area of 鈥嬧?媋ctive research, and there is growing interest in the potential ofDDX47 as a treatment for this progressive muscle-wasting disease.

One of the main goals of clinical research is to evaluate the safety and efficacy of drugs that target DDX47. Studies have shown that medications that modify DDX47 activity, such as rapamycin and turnip, have the potential to increase muscle strength and function in individuals with dystonia.

While further studies are needed to determine the exact mechanism of action of these medications and their effectiveness in treating dystonia, the potential of DDX47 as a drug target and biomarker is an encouraging sign.

Conclusion

In conclusion, DDX47 is a protein that has been shown to play a key role in the regulation of muscle strength and function. Its potential as a drug target and biomarker for dystonia is an exciting area of 鈥嬧?媟esearch, and further studies are needed to fully understand its potential and develop effective treatments for this progressive muscle-wasting disease.

Protein Name: DEAD-box Helicase 47

Functions: Required for efficient ribosome biogenesis (By similarity). May have a role in mRNA splicing (PubMed:16963496). Involved in apoptosis (PubMed:15977068)

The "DDX47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets